Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Onyx Pharmaceuticals, Inc. (ONXX), Celldex Therapeutics, Inc. (CLDX): Three Humongous Health-Care Stocks This Week

While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs. Here are three health-care stocks that skyrocketed over the past five days.

Nothing like being wanted

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) experienced the thrill of being wanted this week. Shares soared nearly 57% this week after word leaked last weekend that Amgen, Inc. (NASDAQ:AMGN) offered to buy the company for $120 per share.

By Sunday, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) had announced that it was rebuffing Amgen’s offer as too low. The company also revealed that other third parties had expressed interest in a potential buyout. As a result, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) authorized financial advisor Centerview Partners to line up potential suitors. Mr. Market certainly liked the prospects of a bidding war. During after-hours trading on Friday, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) share prices jumped from $87 to $109. The stock opened on Monday at more than $133 per share. How high can Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) go? Deutsche Bank analyst Robyn Karnauskas pegs the stock’s value at $148 per share. However, Geoffrey Porges at Sanford C. Bernstein thinks some company could pay as much as $180 per share for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).

Buy, buy

Celldex Therapeutics, Inc. (NASDAQ:CLDX) benefited from a couple of “buy” recommendations this week. Many investors appeared to have listened to the advice — shares jumped 36% for the week.

Jim Cramer responded to a caller’s question about Celldex Therapeutics, Inc. (NASDAQ:CLDX) in his Tuesday “Lightning Round” by saying: “I like this one and I’m sticking with it.” Cramer wasn’t the only one saying that the stock was a buy. The next day, Guggenheim initiated coverage on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a “buy” rating and target price of $24 per share. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s lead drug candidate is rindopepimut, which is in a phase 3 study for treating front line glioblastoma and in another phase 2 study for recurrent glioblastoma. The biotech also has several other drugs in its pipeline, including CDX-1135, for which Celldex Therapeutics, Inc. (NASDAQ:CLDX) just kicked off a pilot study in treating dense deposit disease.

Good news comes in threes

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had a triple-whammy of good news this week. Shares shot up by 22% as a result.

The company reported positive results from its phase 2 study of ALN-TTR02 at the beginning of the week.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.